Close

Anti-Peptide QTKRG T cell receptor (13.D5 Y31A), pCDTCR1 (TCR-YC0951)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

13.B1, 13.D5, 14.A6, 14.C6 and T cell hybridomas were constructed from MHCʷᵗ YAe TCRβ Tg mice. 13.D5 Y31A is specific for peptide FEAQTAKARGAVD (abbreviated as QTKRG) in the context of H2-IAᵇ.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • Peptide QTKRG
  • Epitope
  • FEAQTAKARGAVD
  • Format
  • Modified TCR
  • Allele
  • H2-IAb
  • Vector Name
  • pCDTCR1
  • Vector Length
  • ~ 8 kb
  • Vector Type
  • Lentiviral vector
  • TCR Clone
  • 13.D5 Y31A
  • Host Species
  • Mouse

Target

  • Introduction
  • The mature T cell repertoire has the ability to orchestrate immunity to a wide range of potential pathogen challenges. This ability stems from thymic development producing individual T cell clonotypes that express T cell receptors (TCR) with unique patterns of antigen reactivity. The antigen specificity of TCRs is created from the combinatorial pairing of one of a set of germline encoded TCR variable (V) alpha and V beta gene segments with randomly created CDR3 sequences.

Customer Reviews and Q&As

There are currently no customer reviews or questions for Mouse anti-Peptide QTKRG T cell receptor (13.D5 Y31A), pCDTCR1 (TCR-YC0951). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.